On March 19, 2025 Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, reported it has changed its corporate name to Niagen Bioscience, Inc. ("Niagen Bioscience" or the "Company") and the Company’s common stock will begin trading under the new Nasdaq symbol "NAGE" at stock market open today, Wednesday, March 19, 2025 (Press release, ChromaDex, MAR 19, 2025, View Source [SID1234651885]). The CUSIP number for the Company’s common stock will remain the same.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ChromaDex Evolves into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ with Precision Science

Share
With a legacy spanning over 25 years, this strategic evolution underscores the Company’s true identity as the pioneer of NAD+ research and innovator behind transformative NAD-boosting healthy-aging solutions. At the forefront is Niagen Bioscience’s clinically proven, patented flagship nicotinamide riboside (NR) ingredient, Niagen – the most well-researched, efficient, and high-quality, and legal NAD+ booster available.

"This is more than a name change; this is a turning point in our story," said Rob Fried, CEO of Niagen Bioscience. "We have achieved several scientific, financial, and strategic milestones. As Niagen Bioscience, the global leader in NAD+ science and commerce, we have the opportunity to help every living being around the world age better."

Building on a 25+ year legacy, Niagen Bioscience’s renewed mission is simple yet powerful: "There’s a better way to age." The Company remains dedicated to addressing one of life’s most complex challenges—aging. Embodying precision science, Niagen Bioscience is distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and independent research collaborations with renowned investigators and institutions worldwide.

Niagen Bioscience’s clinically proven product portfolio, Tru Niagen and Niagen Plus, is the pinnacle of NAD+ supplementation. Tru Niagen, the Company’s consumer supplement featuring clinically proven food-grade Niagen (patented NR), is the number one NAD+ boosting oral supplement in the United States†. Niagen Plus features pharmaceutical-grade Niagen (NR), compounded by U.S. FDA-registered 503B outsourcing facilities. It is available by prescription as intravenous (IV) and injectable Niagen. Niagen Bioscience is the first company in the U.S. to offer a novel branded ingredient (Niagen) both as a direct-to-consumer dietary supplement (Tru Niagen) and as an intravenous and injectable pharmaceutical-grade product (Niagen IV).

"Our new identity creates a stronger foundation for expanding scientific discoveries and opens doors for potential future strategic partnerships across the bioscience and healthcare sectors," added Mr. Fried. "With this name change, we are celebrating that Niagen is a household name synonymous with healthy aging."

Niagen Bioscience recently reported its fourth quarter and full-year 2024 financial results, with strong full-year net sales at $99.6 million, up 19% from the prior year, and $44.7 million in cash and no debt position. Niagen Bioscience continues to lead the NAD+ space and is reinforced by strong financial results, Tru Niagen’s position as the number one NAD+ boosting supplement in the United States†, the onboarding of Niagen IV at 475 clinics nationwide, and the Company’s distinctive external research program, which has generated over 35 human clinical studies on Niagen.

To mark this milestone today, the Niagen Bioscience executive team will participate in the Nasdaq Closing Bell Ceremony on March 19, 2025, the same day as the official announcement. A live-stream of the Nasdaq Closing Bell Ceremony will take place at www.nasdaq.com at 3:50 pm ET / 12:50 pm PT. This event symbolizes the Company’s next chapter as the pioneer of NAD+ and healthy-aging science.

To learn more about Niagen Bioscience’s bold new chapter, visit www.niagenbioscience.com. Follow the Company’s news, research milestones, and announcements on social media here View Source